We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




FDA Clears New Blood Test to Aid in Diagnosis of Mastocytosis

By LabMedica International staff writers
Posted on 30 May 2012
The US Food and Drug Administration (FDA; Silver Spring, MD, USA) has now approved the use of a tryptase assay to provide a more specific diagnostic tool to physicians suspecting cases of systemic mastocytosis. More...
The assay is also pending approval for use in diagnosing systemic anaphylaxis.

Mastocytosis, the group of rare chronic disorders found in children and adults, is caused by an excess of mast cells, cells normally vital to the inflammatory process and may play protective roles in wound healing and fighting infections. An abnormal burden of the chemicals released from too many of these cells can cause several symptoms ranging in intensity from mild to severe. The symptoms of mastocytosis are often similar to an allergic reaction; however, mastocytosis may occur spontaneously rather than be triggered by an allergen.

The newly approved test, ImmunoCAP Tryptase, measures the level of tryptase in the blood and provides a biochemical indicator on the basis that a persistently elevated baseline level of tryptase is known to be an indication of possible mastocytosis.

The assay was developed by the laboratory led by mast cell expert Lawrence Schwartz, MD, PhD, at Virginia Commonwealth University (VCU; Richmond, VA, USA). Dr. Schwartz, chair of the Division of Rheumatology, Allergy and Immunology and the Charles and Evelyn Thomas, professor of Medicine at VCU, noted, “A physician cannot diagnose systematic mastocytosis based only on a physical examination. The FDA approval of the tryptase assay will provide doctors with an additional diagnostic tool.”

VCU first licensed the tryptase assay in 1993 to Pharmacia, now named Thermo Fisher Scientific, Inc. (Waltham, MA, USA). The assay is being further reviewed by the FDA for additional potential applications, including diagnosis of systemic anaphylaxis, prediction of increased risk for future episodes of severe anaphylaxis, and use by medical examiners to evaluate cause of death. “When somebody dies without a clear cause, by measuring postmortem tryptase levels, an increased level of tryptase provides support for an anaphylactic event near the time of death,” said Dr. Schwartz.

Related Links:

Virginia Commonwealth University
Thermo Fisher Scientific, Inc.
US Food and Drug Administration



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
ESR Analyzer
TEST1 2.0
New
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.